Searle PF - Search Results

1

In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.

Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF, Kerr DJ. Chung-Faye GA, et al. Among authors: searle pf. Gene Ther. 2001 Oct;8(20):1547-54. doi: 10.1038/sj.gt.3301557. Gene Ther. 2001. PMID: 11704815

2

Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.

Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF. Green NK, et al. Among authors: searle pf. Cancer Gene Ther. 1997 Jul-Aug;4(4):229-38. Cancer Gene Ther. 1997. PMID: 9253508

3

Adenoviral vectors: not to be sneezed at.

Searle PF, Mautner V. Searle PF, et al. Gene Ther. 1998 Jun;5(6):725-7. doi: 10.1038/sj.gt.3300686. Gene Ther. 1998. PMID: 9747451 No abstract available.

4

Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells.

Gilligan MG, Knox P, Weedon S, Barton R, Kerr DJ, Searle P, Young LS. Gilligan MG, et al. Gene Ther. 1998 Jul;5(7):965-74. doi: 10.1038/sj.gt.3300672. Gene Ther. 1998. PMID: 9813668

5

Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene.

Searle PF, Weedon SJ, McNeish IA, Gilligan MG, Ford MJ, Friedlos F, Springer CJ, Young LS, Kerr DJ. Searle PF, et al. Adv Exp Med Biol. 1998;451:107-13. doi: 10.1007/978-1-4615-5357-1_17. Adv Exp Med Biol. 1998. PMID: 10026858 No abstract available.

6

Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.

McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF. McNeish IA, et al. Among authors: searle pf. Gene Ther. 1998 Aug;5(8):1061-9. doi: 10.1038/sj.gt.3300744. Gene Ther. 1998. PMID: 10326029

7

Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium.

Gerin PA, Gilligan MG, Searle PF, Al-Rubeai M. Gerin PA, et al. Among authors: searle pf. Hum Gene Ther. 1999 Aug 10;10(12):1965-74. doi: 10.1089/10430349950017329. Hum Gene Ther. 1999. PMID: 10466630

8

Gene therapy strategies for colon cancer.

Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Chung-Faye GA, et al. Among authors: searle pf. Mol Med Today. 2000 Feb;6(2):82-7. doi: 10.1016/s1357-4310(99)01598-1. Mol Med Today. 2000. PMID: 10652481 Review.

9

Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.

Latham JP, Searle PF, Mautner V, James ND. Latham JP, et al. Among authors: searle pf. Cancer Res. 2000 Jan 15;60(2):334-41. Cancer Res. 2000. PMID: 10667585

10

Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.

Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ, Wrighton CJ. Djeha AH, et al. Among authors: searle pf. Cancer Gene Ther. 2000 May;7(5):721-31. doi: 10.1038/sj.cgt.7700171. Cancer Gene Ther. 2000. PMID: 10830719

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters